Food and Drug Administration
[Docket No. FDA-2015-N-0540]
Homeopathic Product Regulation: Evaluating the Food and Drug Administration's Regulatory Framework After a Quarter-Century; Public Hearing

Presenter: Dr Peter Fisher MB,BChir, FRCP, FFHom

Presentation Outline

1) Background / Credentials
    a. Current positions:
        i. Clinical director and director of research, Royal London Hospital for Integrated Medicine
        ii. Fellow, Royal College of Physicians and of the Faculty of Homeopathy
    b. Accreditation, board certification, and degree
        i. Homeopathy
        ii. Rheumatology
    c. Affiliations
        i. National Institute for Health and Care Excellence's external advisory panel
        ii. WHO Expert Advisory Panel on Traditional and Complementary Medicine

2) Consumer/patient attitudes toward homeopathy
    a. Patients report benefit
        i. Patient outcomes surveys show condition improvement has impact on daily lives
    b. Growth and use in Europe
        i. UK = 10% growth
        ii. France = 98% of retail pharmacies stock homeopathy products; >50% of consumers report use
        iii. Germany = 30-40% of consumers report use

3) Healthcare provider attitudes toward homeopathy
    a. Favorable, especially in insurance-based systems

4) Data sources
    a. CORE-HOM database
        i. Searchable by diagnosis, trial design, and medication use
        ii. Comparative effectiveness research

5) Consumer labeling
    a. Education on homeopathic vs herbal
    b. Distinctions on label & in-store supporting materials